Clinical Trial Update: Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial [Phase 2]

View source ↗

Summary

A randomized phase II trial evaluating perioperative NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• FLUOROURACIL (Fluorouracil)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Onivyde (liposomal irinotecan) (liposomal irinotecan)

Snippet

Sponsor: Taichung Veterans General Hospital | Conditions: Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: RECRUITING